TBC1D5

Across TCGA pan-cancer cohorts, TBC1D5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TBC1D5 data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher TBC1D5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TBC1D5 expression acts as an unfavorable survival marker.

KIRC, SARC, and LUSC are the cancer types where TBC1D5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.235	0.806	<.001	36	view →
SARC	DFS	Median	All	0.037	0.632	<.001	12	view →
LUSC	OS	Median	All	0.138	0.818	.003	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TBC1D5–KIRC (OS)

Open the KIRC breakdown →